Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Rhinology‐specific priority setting for quality improvement: a modified Delphi study from the Quality Improvement Committee of the American Rhinologic Society
Rudmik, Luke , Mattos, José L. , Stokken, Janalee K., Manes, R. Peter , Setzen, Michael, Lee, Jivianne, Schneider, John S. , Stokken, Janalee K. , Soler, Zachary M. , Higgins, Thomas S , Lee, Jivianne T. , Carlson, Matthew L , Mattos, Jose

Mayo Clinic

International Forum of Allergy & Rhinology | August 11, 2017 | Volume: 7 | Issue: 10 | Pages: 937-944

10.1002/alr.21998 | PMID 28799731 Get It

BackgroundImproving the quality of healthcare is a complex and resource intensive process. To optimize the allocation of scarce resources, quality improvement (QI) should focus on high‐value diseases that will produce the largest improvement in health system performance. Given the breadth and multidisciplinary nature of sinonasal disease management, the purpose of this study was to transparently develop a prioritized list of sinonasal diseases for QI from the perspective of the specialty of rhinology and the American Rhinologic Society (ARS).MethodsThe RAND modified Delphi methodology was used to rank the priority of nine sinonasal disease categories from 1 (lowest priority) to 9 (highest priority). Two rounds of ranking along with a teleconference meeting was performed by a panel of 9 experts from the ARS Quality Improvement Committee.ResultsThe final QI‐prioritized list of sinonasal diseases are as follows: chronic rhinosinusitis (CRS) (mean score = 8.9), recurrent acute rhinosinusitis (RARS) (mean score = 7.9), sinonasal neoplasms (mean score = 7.0), anatomic nasal obstruction (mean score = 5.9), refractory epistaxis (mean score = 5.2), complicated acute rhinosinusitis (mean score = 5.2), chronic nonallergic rhinitis (mean score = 4.4), orbital disease (mean score = 4.3), uncomplicated acute rhinosinusitis (mean score = 4.1), and allergy/allergic rhinitis (mean score = 3.7).ConclusionThe three most important disease categories for QI from the perspective of the specialty of rhinology were CRS, RARS, and sinonasal neoplasms. Future studies need to define and validate quality metrics for each of these important disease categories in order to facilitate appropriate measurement and improvement initiatives.
Ablation of Musculoskeletal Metastases
Callstrom, Matthew R. , Kurup, A. Nicholas , Morris, Jonathan M.

Mayo Clinic

American Journal of Roentgenology | August 4, 2017 | Volume: 209 | Issue: 4 | Pages: 713-721

10.2214/ajr.17.18527 | PMID 28777648 Get It

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, Michael , Neelapu, Sattva S. , Farooq, Umar , Neste, Éric Van Den, Westin, Jason R. , Link, Brian K. , Hay, Annette E. , Zhu, Liting , Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian , Link, Brian K , Farooq, Umar , Westin, Jason R , Kuruvilla, John , Cerhan, James R. , Boussetta, Sami , Feng, Lei , Maurer, Matthew J.

Mayo Clinic

Blood | August 3, 2017 | Volume: 130 | Issue: 16 | Pages: 1800-1808

10.1182/blood-2017-03-769620 | PMID 28774879 Get It

Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.
Skeletal and Uterotrophic Effects of Endoxifen in Female Rats
Gingery, Anne , Subramaniam, Malayannan , Turner, Russell T. , Pitel, Kevin S., McGovern, Renee M., Marler, Ronald J., Hawse, John R. , Reid, Joel M. , Ingle, James N. , Iwaniec, Urszula T. , Goetz, Matthew P. , Gingery, Anne

Mayo Clinic

Endocrinology | August 3, 2017 | Volume: 158 | Issue: 10 | Pages: 3354-3368

10.1210/en.2016-1871 | PMID 28977607 Get It

The Disputed Discovery of Facial and Trigeminal Nerve Function: Revisiting the Contributions of Herbert Mayo and Charles Bell
Carlson, Matthew L. , Bradley, James , Tubbs, R. Shane , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | August 2, 2017 | Volume: 38 | Issue: 9 | Pages: 1376-1381

10.1097/mao.0000000000001535 | PMID 28777228 Get It

Background: The first description of the voluntary motor function of the facial nerve and separate sensory-motor contributions of the trigeminal nerve is most commonly attributed to Charles Bell. However, a review of the original scientific accounts and subsequent historical publications question the validity of this credit. The objective of the present historical analysis is to clarify the contributions of Herbert Mayo toward discovering the functions of the fifth and seventh cranial nerves and to raise awareness of this historical controversy within the medical literature. Methods: Review of Charles Bell's and Herbert Mayo's original dissertations published between 1821 and 1823, and subsequent reports relevant to these primary works. Results: Bell's submissions to the Royal Society of London in 1821 and 1822 describe the seventh nerve as the “respiratory nerve of the face” responsible for involuntary coordination of facial movement with the organs of respiration. Separately, Bell states that the fifth nerve is responsible for sensibility and voluntary movement of the facial muscles. In these accounts, Bell only peripherally alludes to the motor function of the seventh nerve and often comments inaccurately on fifth and seventh cranial nerve innervation. In contrast, in 1822 and 1823, Herbert Mayo first accurately and unequivocally defined the voluntary motor function of the facial nerve and sensory-motor function of the trigeminal nerve on the basis of his detailed experiments. The ultimate transfer of acknowledgment to Bell was rooted in surreptitious reworking of Bell's original dissertations and personal attacks against Mayo rather than arguments of scientific merit. Conclusion: Several notable clinicians and anatomists have contributed to our current understanding of the anatomy and physiology of the facial and trigeminal nerves, including Charles Bell; however, Herbert Mayo should be remembered for first providing a more accurate and clear description of their separate functions.
Transcarotid Artery Revascularization With Flow Reversal: Bypassing the Arch and Limiting Distal Emboli
Welz, Matthew E., Sattur, Mithun G. , Richter, Kent R. , Bendok, Bernard R.

Mayo Clinic

Neurosurgery | August 2, 2017 | Volume: 81 | Issue: 5 | Pages: N41-N42

10.1093/neuros/nyx456 | PMID 29088470 Get It

The use of highly crosslinked polyethylene in total knee arthroplasty
Brown, Timothy S. , Berry, Daniel J. , Berry, Daniel J , Citters, Douglas W. Van , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | August 2, 2017 | Volume: 99-B | Issue: 8 | Pages: 996-1002

10.1302/0301-620x.99b8.bjj-2017-0028.r1 | PMID 28768774 Get It

Advances in polyethylene (PE) in total hip arthroplasty have led to interest and increased use of highly crosslinked PE (HXLPE) in total knee arthroplasty (TKA). Biomechanical data suggest improved wear characteristics for HXLPE inserts over conventional PE in TKA. Short-term results from registry data and few clinical trials are promising. Our aim is to present a review of the history of HXLPEs, the use of HXLPE inserts in TKA, concerns regarding potential mechanical complications, and a thorough review of the available biomechanical and clinical data.Cite this article: Bone Joint J 2017;99-B:996–1002.
Neurogenic Orofacial Weakness and Speech in Adults With Dysarthria
Solomon, Nancy Pearl , Makashay, Matthew J., Helou, Leah B. , Solomon, Nancy Pearl , Clark, Heather M.

Mayo Clinic

American Journal of Speech-Language Pathology | August 1, 2017 | Volume: 26 | Issue: 3 | Pages: 951-960

10.1044/2017_ajslp-16-0144 | PMID 28763804 Get It

Purpose This study compared orofacial strength between adults with dysarthria and neurologically normal (NN) matched controls. In addition, orofacial muscle weakness was examined for potential relationships to speech impairments in adults with dysarthria. Method Matched groups of 55 adults with dysarthria and 55 NN adults generated maximum pressure (P max ) against an air-filled bulb during lingual elevation, protrusion and lateralization, and buccodental and labial compressions. These orofacial strength measures were compared with speech intelligibility, perceptual ratings of speech, articulation rate, and fast syllable-repetition rate. Results The dysarthria group demonstrated significantly lower orofacial strength than the NN group on all tasks. Lingual strength correlated moderately and buccal strength correlated weakly with most ratings of speech deficits. Speech intelligibility was not sensitive to dysarthria severity. Individuals with severely reduced anterior lingual elevation P max (< 18 kPa) had normal to profoundly impaired sentence intelligibility (99%–6%) and moderately to severely impaired speech (26%–94% articulatory imprecision; 33%–94% overall severity). Conclusions Results support the presence of orofacial muscle weakness in adults with dysarthrias of varying etiologies but reinforce tenuous links between orofacial strength and speech production disorders. By examining individual data, preliminary evidence emerges to suggest that speech, but not necessarily intelligibility, is likely to be impaired when lingual weakness is severe.
Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)
Cynthia, X. , Bose, Ron , Telli, Melinda L. , Russell, Christy , Forero, Andres , Thomas, Shana , Anderson, J. L. , Bumb, Caroline, Bryce, Richard , Lalani, Alshad S. , Pfeifer, John D. , Hays, Daniel N., Pegram, Mark D. , Blackwell, Kimberly , Bédard, Philippe L. , Al‐Kateb, Hussam , Gao, Feng , Freedman, Rachel A. , Kimmick, Gretchen , Winer, Eric P. , Naughton, Michael J. , Goetz, Matthew P. , Tripathy, Debu , Cobleigh, Melody , Pluard, Timothy , Anders, Carey K. , Anderson, Jill, Banks, Kimberly C. , Lanman, Richard B. , Ellis, Matthew J. , Telli, Melinda L

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: CT011-CT011

10.1158/1538-7445.am2017-ct011 Get It

Abstract Introduction: MutHER is a phase II trial that demonstrated the anti-tumor activity of the pan-HER inhibitor neratinib in HER2mut, non-amplified MBC. The major challenges to accrue to this trial were the large number of pts to screen for the 2-3% HER2mut population and the high rate (24%) of poor quality tumor DNA for sequencing. The goals of this ctDNA study were: 1) the concordance of HER2mut detected by ctDNA versus tumor testing; 2) the incidence of ctDNA HER2mut in HER2 non-amplified MBC; 3) changes in HER2mut variant allele frequency (VAF) on neratinib therapy. Methods: A sample size of 30 negative (neg) controls was needed to ensure 90% confidence if ctDNA testing has &gt;90% specificity in detecting HER2mut. Thus, plasma from MBC pts obtained at screening for MutHER trial (Neg control: 40 pts without HER2mut on tumor testing; Positive (pos) control: 14 pts with known HER2mut who received neratinib) were subjected to Guardant360 ctDNA 70-gene panel sequencing (all exons of HER2 included). ctDNA from the 14 neratinib treated pts were also analyzed at week (wk) 4 and upon progression. ctDNA data from MBC pts clinically tested at Guardant Health were interrogated for HER2mut incidence. Results: Among the 14 pts with tumor pos for HER2mut, ctDNA sequencing identified the same HER2mut in 11, discrepant HER2mut in 1, and neg in 2. The 2 pts with ctDNA neg for HER2mut had progressive disease (PD) and stable disease (SD &gt; 6 months) on neratinib, respectively. Among the 40 neg controls, 8 were not evaluable (no detectable ctDNA or assay unsuccessful) and all 32 successfully sequenced cases were neg for HER2mut. The sensitivity and specificity of ctDNA for HER2mut detection was 11/14 (79%, 90% CI: 53-94%) and 32/32 (100%, 90% CI: 91-100%), respectively. Among the 11 paired baseline and wk 4 samples, 9 (82%) had lower HER2mut VAFs at wk 4 than at baseline, with 1 complete response (CR), 1 partial response (PR), 5 SD, and 4 PD at wk 8 as best tumor response. Two pts had higher wk 4 ctDNA HER2mut VAFs and both had radiographic PD at wk 8. The absolute HER2mut VAF levels at wk 4 were significantly associated with TTP (Spearman rho=-0.69, p=0.02) and tumor size change (rho=0.67, p=0.05). The HER2mut VAFs were significantly higher at progression than wk 4 in all pts (p&lt;0.01). One pt acquired a new HER2mut T798I, which is analogous to the gate-keeper mutation EGFR T790M. The incidence of HER2mut without amplification in unselected consecutive MBC clinically tested by Guardant360 was 3% (48/1,584), with mutation pattern similar to published tumor testing data. Conclusions: ctDNA sequencing is sensitive and highly specific in detecting HER2mut, offering a non-invasive method to identify pts for trials of HER2mut-targeted therapy. Decreased HER2mut VAFs at wk 4 was observed in 82% of cases, consistent with the on-target effect of neratinib. Increased HER2mut VAFs at wk 4 is a potential early marker of progression. Citation Format: Cynthia Ma, Ron Bose, Feng Gao, Rachel Freedman, Melinda Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy Pluard, Carey Anders, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly Banks, Richard Lanman, Richard Bryce, Alshad Lalani, John Pfeifer, Daniel Hays, Mark Pegram, Kimberly Blackwell, Philippe Bedard, Hussam Al-Kateb, Matthew Ellis. Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT011. doi:10.1158/1538-7445.AM2017-CT011
Abstract 489: Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer
Haricharan, Svasti , Schmelz, Jacob , Schmidt, Cheryl, Singh, Purba , Holloway, Kimberly R. , Li, Shunqiang , Kavuri, Shyam M. , Huang, Shixia , Edwards, Dean P., Cynthia, X. , Bainbridge, Matthew N. , Anurag, Meenakshi , Suman, Vera J. , Hunt, Kelly K. , Olson, John A. , Hoog, Jeremy , Ellis, Matthew J.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 489-489

10.1158/1538-7445.am2017-489 Get It

Abstract Estrogen receptor positive (ER+) breast cancer is treated with endocrine therapy but intrinsic resistance occurs in ~1/3 of patients and acquired resistance in ~1/5 of the remainder. While many resistance mechanisms have been explored, therapeutic strategies to overcome resistance in the clinical setting have seen mixed outcomes, and appear most effective in the acquired resistance setting. Understanding mechanisms of resistance and finding therapeutic strategies to target them, therefore, remain important challenges facing breast cancer researchers. In this study we systematically examine the role of DNA damage repair defects in inducing endocrine therapy resistance, a relatively understudied question of recent interest. We use in silico analysis of clinical datasets, in vitro experiments evaluating endocrine therapy resistance in response to DDR dysregulation in multiple breast cancer celllines, and in vivo validation using cellline xenograft and patient-derived xenograft models. We also use gene expression microarrays and RPPA data from cell lines, patient-derived xenografts and primary ER+ breast tumors to uncover therapeutic options that are validated in vitro and in vivo and corroborated by clinical trial data. The results of this study uncover an intriguing link between mismatch repair (MMR) deficiency, specifically of the MutL complex (MLH1/3, PMS1/2), and poor prognosis in ER+ disease. We find a direct role for MutL loss in endocrine therapy resistance in vitro and in vivo by knocking down multiple MutL genes using CRISPR and stable shRNA approaches validated using standard rescue experiments. We identify the underlying mechanism: MutL deficiency in ER+ breast cancer abrogates Chk2-mediated feedback inhibition of CDK4/6 that appears necessary for endocrine therapy responsiveness. Consequently, pharmacological targeting of CDK4/6 in vitro and in vivo significantly inhibits growth of endocrine therapy resistant MutL-deficient ER+ breast cancer cells. These results are corroborated by data from a neoadjuvant clinical trial demonstrating that cell cycle regulation of MutL-mutant tumors tends to be estrogen-independent but sensitive to CDK4/6 inhibitors. The results of this study provide important biological and clinically relevant insights. 1) MMR deficiency is unexpectedly causal to intrinsic endocrine therapy resistance 2) This causal effect appears to be mediated by abrogation of cell cycle checkpoint activation in response to endocrine therapy 3) MMR deficiency in a subset of ER+ tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy resistant tumors. While there are currently no biomarkers to guide the use of CDK4/6 inhibitors for ER+ breast cancer, markers of MMR dysregulation could identify patients in whom CDK4/6 inhibition should be used to prevent disease recurrence. Citation Format: Svasti Haricharan, Jacob Schmelz, Cheryl Schmidt, Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, Shunqiang Li, Shyam M. Kavuri, Shixia Huang, Dean P. Edwards, Vera Suman, Kelly Hunt, John A. Olson, Jeremy Hoog, Cynthia X. Ma, Matthew N. Bainbridge, Matthew J. Ellis. Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 489. doi:10.1158/1538-7445.AM2017-489